Full Name
Shelley Ackerman
Immunotherapy for difficult-to-treat cancers
Brief Biography
Shelley Ackerman is the co-inventor of a novel cancer immunotherapy platform based on her research as a graduate student in Edgar Engleman's lab at Stanford University. This platform, termed Immune Stimulating Antibody Conjugates, is the foundation for the pipeline now being developed by Bolt Biotherapeutics. Shelley is an Associate Director at Bolt Biotherapeutics where she leads a team of researchers driving pre-clinical research to bring novel therapeutics from bench to bedside. Shelley is the first author of a manuscript describing the ISAC technology published in Nature Cancer and was honored as an Innovator Under 35 by the MIT Technology Review and as a STAT Wunderkind in 2021. Prior to completing her PhD in Bioengineering at Stanford University, Shelley received a masters in Bioengineering from Stanford University and a bachelor's degree in Biological Engineering from MIT.
Shelley Ackerman